Skip to main content

FDA Grants Priority Review for Aciphex sNDA

FDA Grants Priority Review for Aciphex (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents

WOODCLIFF LAKE, N.J., February 29, 2008 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has accepted an Aciphex supplemental New Drug Application (sNDA) for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in patients ages 12-16. Further, FDA has indicated that the sNDA will receive priority review in accordance with the Best Pharmaceuticals for Children Act, which provides for a 180-day review period.

Aciphex was discovered and developed by Eisai and is copromoted in the United States with PriCara, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

About Aciphex (rabeprazole sodium)

Aciphex is a prescription medication. One Aciphex 20 mg tablet daily is used in adults for the treatment of persistent, frequent (2 or more days a week) heartburn and other symptoms associated with acid reflux disease.

Aciphex is also used in adults for the short-term (4 to 8 weeks) treatment in the healing and symptom relief of damaging (erosive) acid reflux disease (gastroesophageal reflux disease).

Important Safety Information

Aciphex has a well-established safety profile. The most common side effect possibly related to Aciphex is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin) may need to be monitored more closely by their doctor. To learn more, talk to your doctor and see the full product information at www.aciphex.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

For more information about Eisai, please visit www.eisai.com.

Aciphex is a registered trademark of Eisai Co., Ltd.

Coumadin is a registered trademark of Bristol-Myers Squibb Pharma Company.

CONTACT: Judee Shuler of Eisai Corporation of North America,+1-201-746-2241

Web site: http://www.eisai.com/http://www.aciphex.com/

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2008

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.